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Abstract
Background: Alpha-synuclein (SNCA) gene expression is an important factor in the pathogenesis of Parkinson’s disease (PD).
Gene multiplication can cause inherited PD, and promoter polymorphisms that increase SNCA expression are associated
with sporadic PD. CpG methylation in the promoter region may also influence SNCA expression.
Methodology/Principal Findings: By using cultured cells, we identified a region of the SNCA CpG island in which the
methylation status altered along with increased SNCA expression. Postmortem brain analysis revealed regional non-specific
methylation differences in this CpG region in the anterior cingulate and putamen among controls and PD; however, in the
substantia nigra of PD, methylation was significantly decreased.
Conclusions/Significance: This CpG region may function as an intronic regulatory element for SNCA gene. Our findings
suggest that a novel epigenetic regulatory mechanism controlling SNCA expression influences PD pathogenesis.
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Introduction
Parkinson’s disease (PD) (MIM168600) is a neurodegenerative
disease characterized by akinesia, rigidity, tremor, and postural
instability. The prevalence is more than 1% of the population over
65 years old [1]. Most of the PD cases are sporadic, although 10%
is hereditary and caused by mutations in SNCA, PARK2, LRRK2,
PINK1, UCHL1, or DJ1, in the majority of cases [2]. Mutations in
these genes are occasionally found in sporadic PD; however, the
majority of sporadic cases show no evidence of mutation in any of
the known causative genes.
The pathological hallmark of PD is Lewy bodies (LB), which are
intracellular inclusion bodies consisting of aggregated alpha-
synuclein. Abnormal accumulation of aggregated protein is closely
associated with the pathogenesis of many neurodegenerative
diseases. The precise mechanism of aggregation remains un-
known, but increased expression of aggregation-prone proteins
can lead to their aggregation. For example, in Down syndrome,
duplication of the 21st chromosome, which contains the amyloid
beta precursor protein (APP) gene, leads to accumulation of
amyloid beta and Alzheimer’s disease pathology [3]. In rare cases
of PD, duplication or triplication of SNCA gene leads to alpha-
synuclein accumulation, with triplication producing a more severe
phenotype than duplication, suggesting that SNCA expression level
determines the severity of the pathology [4,5,6]. Animal models of
neurodegenerative disorders are generated by over-expression of
causal genes, further supporting the conclusion that increased gene
expression is related to pathogenesis [7]. Additional evidence
indicates that SNCA promoter polymorphisms increases alpha-
synuclein expression and increases susceptibility to sporadic PD
[8,9,10]. On the basis of these reports, we hypothesized that there
may be another unknown mechanism for increased SNCA
expression in PD.
In addition to promoter polymorphisms, epigenetic modifica-
tion can alter downstream gene expression. Epigenetic regulation
includes histone modification and DNA methylation, of which
CpG island methylation can be gene-specific; in several different
cancers, CpG methylation inhibits binding of the transcription
machinery, causing silencing of a specific oncogene, which leads to
carcinogenesis [11,12,13]. In central nervous system disorders,
CpG methylation has been associated with psychiatric disorders,
such as autism and schizophrenia [14].
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15522
We sought to identify CpG islands in the SNCA gene, wherein
methylation status was associated with alpha-synuclein expression.
For this purpose, we had to find cell lines which express
endogenous alpha-synuclein at sufficient levels to support a
comparative analysis. To our surprise, we confirmed that non-
neuronal 293 cells express alpha-synuclein protein, and expressed
dopamine receptor genes DRD1 and DRD2. SNCA gene
expression is affected by cell stress, such as serum deprivation,
Interleukin-1b [15], Lipopolysaccharide (LPS) [16], nerve growth
factor (NGF) [17], basic fibroblast growth factor (bFGF) [18], 1-
methyl-4-phenylpyridine (MPP+) [19], and dopamine [20]. By
using these potential alpha-synuclein up-regulators, we have
identified an SNCA CpG island that controls in vitro alpha-
synuclein expression, and then analyzed postmortem brain tissues
to find PD-specific SNCA promoter demethylation in the substantia
nigra.
Methods
Cell culture
HeLa and 293 (HEK-293) cells purchased from ATCC
(Manassas, VA, USA) were grown in Dulbecco’s modified eagle
medium (Sigma, St. Louis, MO, USA) with 10% fetal bovine
serum (BIO Whittaker, Walkersville, MD, USA). SH-SY5Y cells
also purchased from ATCC were grown in Dulbecco’s modified
Eagle’s medium nutrient mixture F-12 HAM (Sigma), with 0.15%
sodium bicarbonate solution (Sigma) and 1 mM sodium pyruvate
(Sigma), at 37uC in 5% CO2 in air. Plasmid transfection was
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s protocol. Interleukin-1b,
Lipopolysaccharide (LPS) (L2654, L6529), human basic fibroblast
growth factor (bFGF), human nerve growth factor (NGF)-b,
dopamine hydrochloride, and haloperidol were purchased from
Sigma. Cell viability assays (MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) as-
says) were performed with CellTiter 96 AQueous One Solution
Reagent (Promega, Madison, WI, USA), according to the
manufacturer’s protocol. OD at 490 nm was measured on a plate
reader Spectramax plus 384 (Molecular Devices, Sunnyvale, CA,
USA).
Protein extraction
Cells were lysed in 50 mM Tris-HCl 7.5, 150 mM NaCl, 1%
NP40, 0.5% sodium deoxycholate, and 1 mM ethylenediamine-
tetraacetic acid (EDTA) supplemented with protease inhibitor
cocktail (complete Mini, EDTA-free, Roche Diagnostics, Mann-
heim, Germany). After SDS-PAGE, proteins were transferred to
an Immobilon transfer membrane (Millipore, Bedford, MA, USA).
For visualization, horseradish peroxidase-conjugated secondary
antibodies were used with ECL Western Blotting Detection
Reagents (GE Healthcare UK limited, Buckinghamshire, UK),
and detected with LAS-3000 mini (Fuji film, Tokyo, Japan).
Nucleic acid analysis
DNAwas extracted using a DNeasy Blood & Tissue kit (QIAGEN,
Hilden, Germany). RNA was extracted by TRIZOLH reagent
(Invitrogen, Carlsbad, CA, USA). Reverse transcription was
performed with ReverTraAce (Toyobo, Osaka, Japan) following
manufacturer’s protocol. Probes for quantitative RT-PCR are as
follows, (SNCA forward primer: 59-CCAGTTGGGCAAGAAT-
GAAGAA-39, reverse primer: 59-CTTGATACCCTTCCTCAG-
AAGGC-39, TaqMan probe: 59-[FAM]AATTCTGGAAGATA-
TGCCTGTGGATCCTGA[TAMRA]-39; DRD1: Hs01024463_
m1, DRD2: Hs00377719_g1, DRD3: Hs00945865_mH, ACTB:
4326315E (for reference)) (Applied Biosystems, Carlsbad, CA, USA).
Analysis was performed on an ABI 7900HT instrument (Applied
Biosystems). Relative expression levels were calculated using
comparative Ct method.
Methylation analysis
Bisulfite sequencing. Methprimer (http://www.urogene.
org/methprimer/index1.html) was used to design primers for
bisulfite sequencing (59-GGGAGGTTAAGTTAATAGGTGG-
TAA-39 and 59-CCCTCAACTATCTACCCTAAACAAAC-39).
Bisulfite conversion was performed with the EpiTect Bisulfite kit
following the manufacturer’s ‘‘low-concentration’’ protocol (QIA-
GEN). For each samples, 100ng of genomic DNA was used and
incubated at 95uC for 5min, 60uC for 25min, 95uC for 5min, 60uC
for 85min, 95uC for 5min and 60CuC for 175min. Converted
product was purified following the instructions of the Epitect
Bisulfite kit. One mL from the final 20 mL elute was PCR-amplified
with LA Taq (Takara) following the manufacturer’s mixture
condition and 30 PCR cycles of 98uC 10sec, 55.5uC (for CpG-1)
or 63uC (for CpG-2) 30sec, 68uC 60sec. The PCR product was
cloned to pCR9-TOPO vector (Invitrogen). At least 20 clones from
each experiment were sequenced by M13 reverse or M13 forward
(220) primers. There are 21 CpH sequences in the region. We
used sequence results up to 3 unconverted CpHs for further
analysis. For each samples, patterns of methylation and uncon-
verted CpHs were used to detect similar clones. Up to four
overlapping clones were allowed for measuring CpG methylation.
Data analysis and methylation patter figures were generated using
QUMA software [21].
Methylated-CpG Island Recovery Assay. A MethylCo-
llector kit (Active Motif, Carlsbad, CA, USA) was used to perform
the methylated-CpG island recovery assay (MIRA). The
experiment was performed as instructed by the manufacturer.
The methylated DNA target fragment was detected with PCR
primers 59-AGCTGCGTTTGGCAAATAAT-39 and 59-GCC-
CAAGTGTGATGGTTCTAA-39.
Dual-Luciferase assay
CpG-2 was amplified by primers 59- TGTGGAGAAGCA-
GAGGGACT -39, 59- ACAGGTTGATGGTGGAAAG -39 and
cloned into pMOD shLuc (InvivoGen, San Diego, CA, USA)
which encode firefly luciferase and the entire plasmid was
demethylated in JM110 (Stratagene, La Jolla, CA, USA). In vitro
CpG methylation was performed by incubation with M.SssI (New
England Biotechnology, Cambridge, MA, USA) for 1 h at 37uC.
Methylated and non-methylated plasmids were transfected into
293 cells with pGL4.74 [hRluc/TK] (Promega) to use sea pansy
luciferase as an internal control calibrator. Dual-luciferase activity
was measured using the Pick&gene luciferase detection kit (Toyo
B-Net co, Tokyo, Japan) on a plate reader Phelios AB-2350
(ATTO, Tokyo Japan). Firefly activity was normalized by sea
pansy activity to calibrate background and transfection efficiency.
Postmortem brain
Postmortem brains were obtained at University of Tokyo
Hospital, University of Tsukuba Hospital, and National Hospital
Organization Tokyo Hospital, with written consent from patients’
families and approval of the ethical committees of each facility.
Specimens were maintained at 280uC until analysis. Pathological
diagnosis was made by neuropathologists using hematoxylin-eosin,
Nissl, silver staining together with immunostaining by phosphor-
ylated tau (AT8, Innogenetics) and phosphorylated alpha-
synuclein antibodies (psyn#64, Wako, Japan) following the
established criterias [22,23].
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Statistic analysis
Statistical analysis was performed with the aid of Instat3
software (Graphpad Software, Inc, LaJolla, CA). Significance was
tested with ANOVA and Student’s t-test.
Results
Dopamine alters SNCA CpG island methylation and
enhances alpha-synuclein expression
Our first goal was to identify the region of the SNCA CpG island
responsible for transcription regulation. We tested various human
cell lines for endogenous alpha-synuclein expression. Immuno-
blotting revealed that 293 cells, although not neuronal, expressed a
significant amount of alpha-synuclein. In fact, the expression in
293 cells was considerably greater than in SH-SY5Y cells, which
are often considered to be dopaminergic; thus, we decided to use
293 cells for further analysis.
Using 293 cells, we tested various drugs that have been reported to
alter alpha-synuclein expression. Of 6 reagents tested, 1 lipopolysac-
charide and dopamine caused a significant increase in the production
of alpha-synuclein (Figure 1B). Because dopamine seemed to enhance
alpha-synuclein expression more than the lipopolysaccharide, we
chose to analyze its effect on SNCA CpG island methylation.
The SNCA gene has two CpG islands, predicted by CpG
detection software (Figure 1C). One of the CpG islands (CpG-1) is
located at the first exon, which is not a coding region for alpha-
synuclein. The second CpG island (CpG-2) is located in the first
intron. We analyzed the methylation status of CpG-1 and -2 by
MIRA to test the effect of dopamine. CpG-1 methylation
remained unchanged whereas CpG-2 methylation was decreased
by the addition of 100 mM dopamine (Figure 1D). Since MIRA is
a robust but not a sensitive method for measuring methylation, we
next evaluated methylation with the more sensitive bisulfite
sequencing method.
CpG-2 has 13 CpG sequences (Figure 2A). CpG-2 was 94.4%
methylated at baseline, and decreased in a dose-dependent
manner with the addition of dopamine (0 mM, 94.4%; 50 mM
72.0%; 100 mM 21.2%) (Figure 2B). Bisulfite sequencing analysis
of CpG-1 revealed no significant change in methylation with the
addition of dopamine (0 mM, 7.2%; 50 mM 3.3%; 100 mM
6.7%, figure not shown).
We next tested the correlation between dopamine induction of
alpha-synuclein expression and CpG-2 demethylation. Addition of
100 mM dopamine further increased the expression of alpha-
synuclein mRNA (Figure 3A). Since alpha-synuclein expression is
affected by the cellular stress response [24], we tested whether
Figure 1. Identification of SNCA CpG islands. A: 293 cells express endogenous alpha-synuclein Immunoblot of cell lysates from SH-SY5Y, 293,
and HeLa cells with or without over-expression of wild-type alpha-synuclein (transfection2 and +). Arrow indicates alpha-synuclein. B: Quantification
of alpha-synuclein expression in the presence of various stimuli. DMSO (2), IL-1b (100 ng/mL), lipopolysaccharides (L2654 and L6529 1 mg/mL), bFGF
(100 ng/mL), NGF (100 ng/mL) and dopamine (DA 50 mM) were added to 293 cells for 48 h and relative expression of alpha-synuclein was compared
by quantitative RT-PCR. Relative amounts of alpha-synuclein mRNA were normalized to DMSO=1.0, * P,0.01, ** P,0.001. C: Structure of the SNCA
CpG island Entrez gene NC_000004.11 ID was analyzed by CpG island search software (http://www.uscnorris.com/cpgislands2/cpg.aspx.). Non-coding
exon1 and coding exon2 are indicated by open arrows. The translation start ATG codon (methionine) located at exon2 is indicated by a closed circle.
Two separate CpG islands are indicated by closed bars. D: Methylated-CpG island recovery assay of dopamine treated cells. 293 cells treated with or
without dopamine were lysed and methylated. CpGs were enriched by MBD2 protein. Methylated CpG-1 or CpG-2 was detected by PCR before and
after enrichment.
doi:10.1371/journal.pone.0015522.g001
SNCA CpG Hypomethylation in PD
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dopamine caused cellular stress at the experimental concentration,
and found that 100 mM dopamine did not alter cellular viability,
as measured by the MTS method (Figure 3B). We conclude,
therefore, that demethylation was not caused non-specifically by
dopamine toxicity, but is the result of a more direct mechanism.
Finally, we tested whether CpG-2 methylation was essential for
downstream gene expression. In vitro methylated CpG-2 had a
significant negative effect on down-stream gene expression, as
measured by luciferase assays (Figure 3C). Thus, we concluded
that CpG-2 methylation was essential for alpha-synuclein
expression.
Methylation status of CpG-2 controls alpha-synuclein
expression through dopamine receptor signaling
We next tried to understand the underlying mechanism of CpG-
2 demethylation. Since 293 cells are not neuronal and there is little
knowledge regarding their response to dopamine, we tested 293
cells for expression of dopamine receptors. Quantitative PCR
clearly showed that 293 cells expressed DRD1 (D1 receptor) and
DRD2 (D2 receptor), at levels comparable to those of dopami-
nergic SH-SY5Y cells (Figure 3E). To determine whether
demethylation of SNCA CpG-2 was receptor mediated, we added
haloperidol, a D2 receptor antagonist, along with dopamine, and
Figure 2. Dopamine induced demethylation of CpG-2. A: Location of CpGs in the second SNCA CpG island. There are 13 CpGs in the CpG-2
region. Each CpG is labeled above according to its positions from the 59 end of the sequence. GATA transcription factor recognition sequence is
shown with an under bar. B: Bisulfite sequence analysis of the CpG-2 region. Dopamine (DA; 0, 50, and 100 mM) was added to 293 cells. DNA was
purified and bisulfite sequence analysis was performed. At least 20 clones from each dopamine-treated group were analyzed. Open circles indicate
unmethylated CpGs, whereas closed circles indicate methylated CpGs. The degree of methylation was calculated as methylated CpG/total CpG and
shown below (% methylation).
doi:10.1371/journal.pone.0015522.g002
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found that haloperidol clearly inhibited the effect of dopamine
(Figure 3F). These results strongly suggested that the effect of
dopamine on CpG-2 demethylation was a D2 receptor-mediated
phenomenon, rather than a direct effect of dopamine on the
genome.
Significant demethylation of CpG-2 in the substantia
nigra of PD patients
Since the CpG-2 region was associated with increased
expression of alpha-synuclein in vitro, we next analyzed the
methylation level of this region in the postmortem brain. Twelve
brains from PD, Dementia with Lewy Bodies (DLB), and 7 from
non-neurodegenerative patients were analyzed. The summary of
clinical information and the availability of the brain regions from
each case are shown in Tables 1 and 2.
Bisulfite sequence analysis was performed for all available brain
regions and the % methylation was plotted against various clinical
parameters (Figures S1, S2, S3). When we compared methylation
status of the anterior cingulated cortex and the putamen in
controls and PD/DLB patients, there were no significant
correlations (Figure 4A, B, D, E). However, methylation status
of the substantia nigra was significantly lower in PD patients than
in the controls (Figure 4F) and was unaffected by age (Figure 4C).
Finally, we plotted % methylation against disease duration and
found that in ‘‘normally’’ methylated DLB case, the disease
duration was shorter than the PD cases (Figure 5A–C) suggesting
extension of Lewy body pathology correlates with CpG-2
hypomethylation.
Discussion
Identification of CpG-2 as SNCA regulator
We analyzed the effects of several reagents on alpha-synuclein
expression in 293 cells and found that dopamine had the most
pronounced effect without affecting cell viability. We also tried to
screen reagents that altered CpG methylation along with increased
alpha-synuclein expression level in SH-SY5Y cells; however,
reagents we used did not increase its expression level without
affecting cell viability significantly. To avoid the possibility of CpG
demethylation by cell death, we decided to use 293 cells instead of
SH-SY5Y cells.
Using dopamine as a modulator of SNCA expression, we
searched for a CpG island which exhibited altered methylation
which correlated with changes in gene expression. Of 2 CpG
islands identified in the SNCA gene, we located the second CpG
island at the first intronic region, and found that it showed a
significant decrease in methylation, associated with induction of
alpha-synuclein expression. This was first identified by MIRA
method [25] and was confirmed by bisulfite sequencing [26],
which yielded comprehensive results.
Figure 3. CpG-2 demethylation up-regulates SNCA expression through dopamine receptor signaling. A: Dose dependent up-regulation
of alpha-synuclein by dopamine. RNA was extracted from cells treated with the indicated dopamine concentration for 48 h and quantitative PCR was
performed. The relative amount of alpha-synuclein mRNA against beta-actin was normalized to dopamine= 0. * P,0.05 vs. DA= 0. B: Dopamine does
not affect cell viability. MTS assay was performed after addition of dopamine for 48 h. P = 0.1559 with ANOVA. C: Methylation of CpG-2 suppresses
downstream gene expression. Luciferase assays were performed after transfection of a CpG-free firefly luciferase vector harboring the CpG-2 region at
the 59 of the luciferase gene. The vector was treated with (+) or without (-) CpG methyltransferase prior to transfection. Sea pansy luciferase was co-
transfected as an internal control. Relative luciferase activity was calculated by dividing firefly luciferase activity by sea pansy luciferase activity and
normalized to methylation (2) as 100%. Bars indicate standard error. * P = 0.0025. D: 293 cells express D1 and D2 dopamine receptors. Expression of
DRD1,22 and23 were analyzed in HCN-2, SH-SY5Y, and 293 cells by quantitative RT-PCR. Relative amounts of each receptor are normalized to HCN-
2 = 1. E: A D2 receptor antagonist ameliorates the demethylation effect of dopamine. Dopamine (DA)- and haloperidol-treated 293 cells were lysed
and methylated CpGs were enriched by MBD2 protein. Methylated CpG-2 was detected by PCR before and after enrichment.
doi:10.1371/journal.pone.0015522.g003
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CpG-1 lies from the 59 end of SNCA exon1 throughout the exon,
and CpG-2 is located at intron1. Methylated CpGs in promoter
regions regulate the expression of downstream genes via inhibition
of transcription factor binding. Although the precise regulatory
mechanism for SNCA transcription is unknown, transcription factors
GATA at CpG-2 (Figure 2A) [27] and ZSCAN21 [28] at upstream
of CpG-2 have been reported to bind at intron1. In addition to this,
gamma-synuclein, a close homolog of alpha-synuclein, is reported to
have a similar regulatory region [29]; we thus concluded that CpG-
2 in intron1 was a methylation dependent regulatory element of
SNCA. We found that 293 cells expressed D1 and D2 receptors,
which supported the rationale for our investigation of dopamine-
mediated CpG demethylation in this cell line although they are not
neuronal cells. Additional experiments showed that haloperidol, the
D2 receptor antagonist, clearly inhibited demethylation by
dopamine; thus we concluded that this demethylation was mediated
by dopamine receptor D2. D2 receptor activation is coupled with G
protein Gai, which increases phosphodiesterase activity. CaMK and
the protein kinase C pathway are activated by degradation of cAMP
by phosphodiesterase [30]. This signaling pathway may be
responsible for CpG-2 demethylation.
CpG-2 is significantly hypomethylated only in the
substantia nigra of PD patients
Previous studies have compared alpha-synuclein expression in
postmortem brain or peripheral blood from PD patients, with
inconsistent results, partly because of artifacts of sample quality and
degradation of RNA extracts from postmortem brain tissue
[31,32,33]. In contrast to these, CpG methylation is reported to be
stable up to 48 hours post mortem [34] and we also confirmed that in
mice brain, methylation level of SNCA CpG were stable up to
24 hours (Figure S5). These reports support the relevance of
investigating SNCA CpG methylation in postmortem brains to derive
Figure 4. Analysis of CpG-2 methylation level in various brain regions. A–C: CpG-2 methylation was analyzed by bisulfite sequencing and
plotted against age. Data from anterior cingulate cortex (control: n = 8, PD/DLB: n = 12) (A), putamen (control: n = 4, PD/DLB: n = 7) (B), and substantia
nigra (control; n = 3, PD/DLB: n = 4) (C) are shown. Closed circle = controls, open box =PD/DLB. In figure 4C, age and % methylation had no significant
correlation P= 0.2321. D–F: CpG-2 methylation was analyzed by bisulfite sequencing method and plotted by disease groups. Data from anterior
cingulate cortex (D), putamen (E) and substantia nigra (F) are shown. Closed circle = controls, open box= PD, closed box=DLB P,0.0001 vs. control.
doi:10.1371/journal.pone.0015522.g004
Table 2. Statistical representation of the clinical information on the postmortem brains.
Age at death Brain weight Post-mortem time Disease duration
(y.o.) (g) (h) (yrs)
Non-PD/DLB control 73.469.3 987.563.5 7.4265.48 _
PD/DLB 76.466.1 1251.96191.7 9.5368.3 16.8612.8
Age at death (P = 0.41), brain weight (P = 0.1), postmortem time (P = 0.59) to autopsy are not significantly different between disease and control groups.
doi:10.1371/journal.pone.0015522.t002
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conclusions regarding gene expression. SNCA CpG-2 methylation
levels differed among subjects and regions tested (Figure 4). This
result was not surprising, since a report regarding analysis of CpG
methylation in various CpGs suggested their diversity by age, sex, and
race [35]. However, the result from substantia nigra was quite
striking; the methylation level was almost zero in the PD group,
whereas in the control group it was almost 100%, suggesting that
methylation in the substantia nigra is an important component of PD
pathogenesis. For concerns about DNA quality from substantia,
nigra, we tested in several ways to assure that those were comparable
between controls and PDs (Figure S4).
The demethylatyion of CpG-2 could be occurring in both
neurons and glial cells especially because in the late disease course,
massive neuronal loss can occur. However, this does not indicate
that our findings is unrelated to the direct pathogenesis, since it has
widely recognized that alpha-synuclein aggregation are observed
also in the astrocytes and oligodendrocytes of PD brains
[36,37,38,39]. In neurodegenerative diseases, it is still a mystery
that neurons in similar functions start to degenerate simultaneous-
ly regardless of their spatial location in the brain. We can speculate
that in the early developmental stage, even before the neuronal
and the glial cells are differentiated, epigenetical abnormality can
occur. After long incubational time, slightly over-expressed alpha-
synuclein can accumulate enough in the neurons to cause PD,
while in the glial cells, efficient protein degradation system or the
cell division might help them to prevent the accumulation.
Global CpG methylation decreases with age, and specific genes,
such as cancer suppressors, are down-regulated by decreased
promoter region CpG island methylation [40]. Our findings suggest
that in PD patients, normally occurring SNCA CpG-2 hypermethy-
lation does not occur, causing over-expression of alpha-synuclein
and leading to its accumulation which, in turn, causes PD.
Supporting Information
Figure S1 Methylation patterns from anterior cingulate
samples generated by QUMA software. Data are presented
similarly as in figure 2B. CpG islands are horizontally and the
clones are vertically plotted.6 stands for unconverted cytosines.
(TIF)
Figure S2 Methylation patterns from putamen samples.
(TIF)
Figure S3 Methylation patterns from substantia nigra
samples.
(TIF)
Figure S4 Quality check of genomic DNA from substan-
tia nigra. A: Electrophoresis of 500ng genomic DNA from
different substantia nigra. No degradation was observed. B: PCR
amplification of CpG-2 region from genomic DNA extracted from
substantia nigras. Equal amplification of the region was seen with
different PCR cycles. Primers used to clone CpG-2 fragment for
luciferase assay experiment was used.
(TIF)
Figure S5 CpG methylation is stable up to 24hours of
postmortem time. A: A sequence of mouse SNCA CpG island
analyzed is shown. There are 13 CpGs. B: C57/BL mice were
sacrificed and kept at RT for indicated hours then the SNCA CpG
methylation was analyzed by bisulfite sequencing. Primers used to
amplify bisufite converted DNA are 59-ATAAAATTGAGGGTTT-
TTTGAATT-39and 59-CTCTAACTCCCTAACTCCTTCAC -39.
Three mice were used for each time points. Bars are SEs.
(TIF)
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